What Happened?
Houston, TX-based Lasergen Appointed Mimi Healy as Chief Executive Officer
About the Company
Lasergen is an emerging biotechnology company focused on commercializing novel technologies for DNA sequencing. Our expertise in nucleotide chemistry and next-generation sequencing has led to a number of key discoveries resulting in both game-changing sequencing chemistry (Lightning Terminators™) and a more accurate sequencing platform. While focusing on the development of current cutting-edge technology, our continued drive for innovation and extensive sequencing knowledge allows us to rapidly evolve and keep pace with fast-changing advances in the sequencing industry.
About the Person
Dr. Healy has more than 20 years of healthcare, molecular diagnostics and biotechnology experience in both US and international markets. Dr. Healy pulls from a broad experience base having served roles in research and development, commercialization and executive management in both startup and established organizations in the past. Her experience includes all aspects of strategic development and implementation, corporate finance and fundraising, product development from research to the clinical validation and the successful market launch of molecular diagnostic systems and test kits. Her last position as President and CEO resulted in the successful financing of a start-up and its profitable exit via acquisition. Her product development skills have placed numerous commercial assays in the market. She serves on several grant review boards, has published in various scientific journals, authored several chapters and filed/received patents. Dr. Healy holds a PhD in Microbiology, MS in Biology, BS in Biology with a minor in Chemistry, and BA in Psychology of Industry and Organizations.
Info Source
Press Release
Short Profile